Most recent by Anne L. Peters, MD
VIDEO: Diagnosis of diabetes requires individualized assessment
BOSTON — In this Healio video exclusive, Anne L. Peters, MD, delineates how the diagnosis of diabetes is heterogeneous and requires clinicians to “individualize our assessment of patients, and therefore our treatment of patients.”
VIDEO: Diabetes ‘champions’ needed to address health inequities
NEW ORLEANS — In part 2 of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about a nonprofit model for expanding access to diabetes care.
VIDEO: Tips for expanding reach of diabetes tech in underserved communities
NEW ORLEANS— In part one of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about using technology in underserved populations to close the diabetes treatment gap.
FDA approves first interchangeable biosimilar insulin
The FDA approved the first interchangeable biosimilar insulin product to improve glycemic control for children and adults with diabetes, part of an effort to provide cost-effective options, according to an agency press release.
CGM scanned only intermittently yields ‘stable’ quality of life, reduces hypoglycemia vs. fingerstick tests
When adults with type 1 diabetes use an intermittently scanned continuous glucose monitor, they do not have to sacrifice quality of life to experience benefits, such as fewer hypoglycemia episodes and hospital visits, according to findings published in Diabetes Care.
FDA authorizes marketing of first interoperable insulin dosing controller
The FDA on Friday authorized marketing of the Tandem Diabetes Care Control-IQ interoperable, automated insulin dosing algorithm, the first dosing controller that can be used with other interoperable diabetes devices, allowing people with diabetes to create a customizable automated insulin delivery system, according to an agency press release.
FDA issues complete response letter for sotagliflozin
The FDA on Friday issued a complete response letter regarding a new drug application for oral sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor for adult with type 1 diabetes, according a press release from Sanofi and Lexicon.